RE:RE:Seems to be room for others in AD Treatment Yes, similar mechanism.
Likely significant different binding targets at the amino acid level.
PMN310 does not bind quite as strongly as lecanumab but binds better or similar than aducanumab and others.
However, PMN310 is more selective, in that it binds less to plaque and other targets, making it much less likely to cause ARIA-E brain swelling, which limits the dosing of aducanumab and lecanumab.
Thus, more PMN310 could be dosed without causing ARIA-E side effects, which may result in higher effectiveness overall as a treatment.
It would be interesting for Promis to do their off-target binding lab assay as a function of PMN310 dose, to see just how they can dose without off-target binding. That would be really helpful data to assess max dosing. I imagine this is something they've been studying ahead of the Ph1 trial. It would be good data to disclose publicly. We'll have some idea once they announce the range of concentrations to be tested in Ph1.
Disclaimer, not a 'medic' , just studied protein binding as part of my graduate studies in another field